This notion is further supported by the observation in patient samples that the incidence of TP53 gene mutations, including missense, truncating and splice site mutations, was about three-fold higher in advanced PCa in SU2C patients (~36.7%) compared to primary PCa in TCGA patients (~12.5%) (Supplementary Fig. 1c) and by the overall survival data in mice (Fig. 1f). Here, TP53 is linked to posterior cortical atrophy.